Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.46 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.46 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL1002904 | 0.96 | KDM4E (0.53) | KDM4EALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL480276 | 0.82 | KDM4E (0.59) | KDM4EALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL30463054 | 0.82 | KDM4E (0.59) | KDM4EALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL2514158 | 0.82 | CTSD (0.56) | KDM4EALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL28837855 | 0.81 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6689608 | 0.81 | NPC1 (0.51) | KDM4EALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL29360359 | 0.81 | MAPT (0.59) | KDM4EALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL29502905 | 0.81 | LMNA (0.57) | KDM4EALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL2066210 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL22588880 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1MAPTHPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025014889-A2 | SEMAGLUTIDE FORMULATIONS | PROCOMPOUNDING, LLC (US) | 2025-01-16 | — | — | WO | claimed |
| CN-114292167-B | Preparation method of vanillin | 万华化学集团股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-116270598-A | Pharmaceutical composition comprising tedenob and use of tedenob in the treatment of breast cancer | 云南大益微生物技术有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-114292167-A | Preparation method of vanillin | 万华化学集团股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3154533-A1 | METHODS OF ANESTHETIZING NERVE TISSUE IN THE TRIGEMINAL NERVE PATHWAY AND MEDICAL USES THEREOF | Loewi LLC (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015195708-A1 | METHODS OF ANESTHETIZING NERVE TISSUE IN THE TRIGEMINAL NERVE PATHWAY AND MEDICAL USES THEREOF | Loewi LLC (US) | 2015-12-23 | — | — | WO | claimed |
| EP-0035770-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A GLYCOSIDIC ANTIBIOTIC AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1986-12-30 | — | — | EP | claimed |
| CN-122031336-A | Whitening and freckle-removing composition based on multi-channel synergy and application thereof | 广州诺彦生物科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260116853-A1 | NEW N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | ATAI THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250388538-A1 | N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | ATAI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250248424-A1 | DEUTERATED CAFFEINE AND USES THEREOF | Lennham Pharmaceuticals, Inc. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12378194-B2 | N, n-dimethyltryptamine salts and crystalline salt forms | ATAI THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-116217376-B | Preparation method of 3-alkoxy-4-hydroxy mandelic acid | 万华化学集团股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-4470980-A | Method of increasing oral absorption of β-lactam antibiotics | INTERX RESEARCH CORP. (US) | 1984-09-11 | — | — | US | disclosed |
| US-4464363-A | HYDROXY ARYL- OR HYDROXY ARALKYL ACIDS OR SALTS | MERCK & CO., INC. (US) | 1984-08-07 | — | — | US | disclosed |
| US-4406896-A | ANTIBIOTICS, ACIDS, HYDROXY | MERCK & CO., INC. (US) | 1983-09-27 | — | — | US | disclosed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | disclosed |
| EP-0035770-A2 | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-16 | — | — | EP | disclosed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116853-A1 | NEW N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | SLC6A4, HTR1D, HTR1A | CA12 1842/4885CA1 856/4885CA2 351/4885 |
| US-20250388538-A1 | N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | SLC6A4, SLC6A2, SLC18A2 | CA12 2380/4885CA1 1914/4885CA2 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.